利伐沙班在初次全髋与全膝关节置换术中的安全性与疗效
本研究基于大型国家数据库,比较2015年1月至2020年12月期间接受初次全髋或全膝关节置换术患者使用利伐沙班、阿司匹林或依诺肝素后的90天出血与血栓栓塞并发症风险。多变量分析显示,与阿司匹林相比,利伐沙班与输血、肺栓塞及深静脉血栓风险增加相关;与依诺肝素相比,利伐沙班与出血事件风险增加但血栓事件风险降低相关。结论认为利伐沙班化学预防与出血及血栓并发症风险增加相关。
要点
- 在全膝关节置换术中,利伐沙班较阿司匹林增加输血风险(aOR=2.58,P<.001)。
- 在全髋关节置换术中,利伐沙班较阿司匹林增加输血风险(aOR=1.64,P<.001)。
- 与依诺肝素相比,利伐沙班增加出血事件风险但降低血栓事件风险。
核心结论
- 利伐沙班在初次全髋和全膝关节置换术后化学预防中,与阿司匹林和依诺肝素相比,与出血及血栓并发症风险增加相关。
研究设计与样本
- 基于大型国家数据库的查询分析,纳入2015年1月至2020年12月期间接受择期初次全髋或全膝关节置换术并使用利伐沙班、阿司匹林或依诺肝素的患者。
- 全膝关节置换术患者中,86,721例(10.8%)接受利伐沙班,408,038例(50.8%)接受阿司匹林,108,377例(13.5%)接受依诺肝素;全髋关节置换术患者中,42,469例(9.5%)接受利伐沙班,242,876例(54.5%)接受阿司匹林,59,727例(13.4%)接受依诺肝素。
- 采用多变量分析评估90天出血和血栓栓塞并发症风险。
主要发现
- 校正混杂因素后,与阿司匹林相比,利伐沙班与输血风险增加相关(全膝关节置换术:aOR=2.58,P<.001;全髋关节置换术:aOR=1.64,P<.001)。
- 与阿司匹林相比,利伐沙班与肺栓塞风险增加相关(全膝关节置换术:aOR=1.25,P=.007)。
- 与阿司匹林相比,利伐沙班与深静脉血栓风险增加相关(全膝关节置换术:aOR=1.13,P=.022)。
- 与依诺肝素相比,利伐沙班与出血事件复合风险增加相关(全膝关节置换术:aOR=1.07,P<.001;全髋关节置换术:aOR=1.11,P<.001)。
- 与依诺肝素相比,利伐沙班与血栓事件复合风险降低相关(全髋关节置换术:aOR=0.85,P=.036)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An optimal venous thromboembolism prophylaxis agent should balance efficacy and safety. While rivaroxaban provides effective venous thromboembolism prophylaxis after total joint arthroplasty, it may be associated with higher rates of bleeding. This study aimed to compare the safety and efficacy of rivaroxaban to aspirin and enoxaparin. METHODS: A large national database was queried for patients who underwent elective primary total hip (THA) or total knee arthroplasty (TKA) from January 2015 through December 2020 who received rivaroxaban, aspirin, or enoxaparin. Multivariate analyses were performed to assess the 90-day risk of bleeding and thromboembolic complications. Among TKA patients identified, 86,721 (10.8%) received rivaroxaban, 408,038 (50.8%) received aspirin, and 108,377 (13.5%) received enoxaparin. Among THA patients, 42,469 (9.5%) received rivaroxaban, 242,876 (54.5%) received aspirin, and 59,727 (13.4%) received enoxaparin. RESULTS: After accounting for confounding factors, rivaroxaban was associated with increased risk of transfusion (TKA: adjusted odds ratio [aOR] = 2.58, P < .001; THA: aOR 1.64, P < .001), pulmonary embolism (TKA: aOR = 1.25, P = .007), and deep vein thrombosis (TKA: aOR = 1.13, P = .022) compared to aspirin. Compared to enoxaparin, rivaroxaban was associated with an increased risk of combined bleeding events (TKA: aOR = 1.07, P < .001, THA: aOR = 1.11, P < .001), but decreased risk of combined prothrombotic events (THA: aOR = 0.85, P = .036). CONCLUSION: Rivaroxaban chemoprophylaxis following TKA and THA was associated with an increased risk of bleeding and prothrombotic complications compared to aspirin and enoxaparin.
引用
- Piple AS, Wang JC, Kang HP, et al. Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty. J Arthroplasty. 2023. PMID: 36805121. doi:10.1016/j.arth.2023.02.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。